Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01303783 · ClinicalTrials.gov registry record · Phase 2
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,381
- Enrollment target
NCT01303783: Completed Phase 2 study, sponsored by Bayer.
NCT01303783 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 1,381 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (938% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01303783, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,381 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the blood pressure lowering responses of various dose combinations of nifedipine GITS and candesartan as compared to treatment with each component on their own (monotherapy) and placebo (a look-alike tablet without active ingredient). The drugs - nifedipine GITS and candesartan - which are being investigated are currently approved for use in patients with essential hypertension alone or together with other antihypertensive drugs (combination therapy), but the optimal dose of nifedipine GITS and candesartan used together in the treatment of essential hypertension has not been established yet. In this study patients will be treated with various doses of nifedipine GITS and/or candesartan or placebo. These different regimens will be administered once a day and will be assessed based on their blood pressure lowering effects (mean sitting diastolic blood pressure) in subjects with mild to moderate essential hypertension.
Interventions
- DRUG Candesartan cilexetil (Atacand), 4 mg
- DRUG Candesartan cilexetil (Atacand), 8 mg
- DRUG Nifedipine GITS (Adalat, BAYA1040), 20 mg
- DRUG Nifedipine GITS (Adalat, BAYA1040), 30 mg
- DRUG Nifedipine GITS (Adalat, BAYA1040), 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,381 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT01303783 record still lists
NCT01303783 is an interventional study that assigns participants to a tested intervention. Its 1,381 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (938% higher).
The record links to 0 conditions, and to 5 interventions - of which Candesartan cilexetil (Atacand), 4 mg is the first listed.
NCT01303783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01303783 about?
NCT01303783 is a clinical study titled "Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension". The purpose of this study is to determine the blood pressure lowering responses of various dose combinations of nifedipine GITS and candesartan as compared to treatment with each component on their own (monotherapy) and placebo (a look-alike tablet without active ingredient). The drugs - nifedipine ...
What is the current status of trial NCT01303783?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,381 participants. The study started on 2011-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01303783?
The interventions under investigation include: Candesartan cilexetil (Atacand), 4 mg (DRUG), Candesartan cilexetil (Atacand), 8 mg (DRUG), Nifedipine GITS (Adalat, BAYA1040), 20 mg (DRUG), Nifedipine GITS (Adalat, BAYA1040), 30 mg (DRUG), Nifedipine GITS (Adalat, BAYA1040), 60 mg (DRUG).
Who is sponsoring clinical trial NCT01303783?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01303783's enrollment target sits among peer trials
1,381 13th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia